Overview

A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese

Status:
COMPLETED

Trial end date:
2024-02-06

Target enrollment:

Participant gender:

Summary

This study aimed to assess the pharmacokinetic profile, safety, and tolerability of a new sustained-release pyridostigmine tablet versus the reference product. The evaluation was conducted in healthy participants following both single and multiple dosing.

Phase:

PHASE1

Details

Lead Sponsor:

West China Second University Hospital

Treatments:

Pyridostigmine Bromide